Gurgaon: Medanta Medicity launches Robotics Lasik unit

Published On 2016-03-10 07:38 GMT   |   Update On 2016-03-10 07:38 GMT

Gurgaon: Medanta Medicity, one of India's largest multi-super specialty institutes located in Gurgaon announced the launch of FemtoLASIK, a revolutionary technology and the most advanced LASIK treatment available in the world that enables bladeless refractive treatment.Speaking on the launch, Dr. Naresh Trehan, Chairman and Founder, Medanta said, “At Medanta, it is our constant endeavour...

Login or Register to read the full article
Gurgaon: Medanta Medicity, one of India's largest multi-super specialty institutes located in Gurgaon announced the launch of FemtoLASIK, a revolutionary technology and the most advanced LASIK treatment available in the world that enables bladeless refractive treatment.

Speaking on the launch, Dr. Naresh Trehan, Chairman and Founder, Medanta said, “At Medanta, it is our constant endeavour to bring the latest medical technologies in the world to Gurgaon and provide the best cure to every patient. The launch of FemtoLASIK showcases our commitment to strengthen our ophthalmology division at the Medicity and provide all encompassing medical treatment under one roof.”

FemtoLASIK technology is the most advanced procedure aimed at improving patient’s quality of life by reducing the dependence on glasses. This world renowned LASIK technology is the current state-of-the-art in refractive surgery. It works by altering the shape of the cornea to treat nearsightedness, farsightedness and astigmatism.

Dr. Sudipto Pakrasi, Chairman, Institute of Ophthalmology at Medanta - The Medicity said, “FemtoLASIK is bladeless and allows the creation of flaps with diameter and thickness of a wide range. It creates very precise, perfect and smooth corneal flaps to ensure accurate treatment with minimum risk. This is the safest LASIK technology available in the world today.”

“With this launch, the Institute of Ophthalmology at Medanta is at par with other renowned medical institutions globally.” Dr. Pakrasi added.

(Press Release)
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News